BTIG lowered the firm’s price target on Glaukos (GKOS) to $114 from $155 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in the MedTech space. The sector had been seen as a safe haven, but quarterly results will matter less than a company’s ability to navigate ahead, the analyst tells investors in a research note. Between a frenetic trade war largely now directed at China to cuts at many federal healthcare agencies, investors will want answers which companies may not be able to provide, and this may weigh on sentiment, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target lowered to $140 from $185 at Truist
- Glaukos Highlights Strategic Focus in 2024 Presentation
- Glaukos, RadiusXR collaborate with Topcon Healthcare on vision testing platform
- Glaukos’s Strong Market Position and Growth Prospects Justify Buy Rating
- FDA gives Glaukos ‘Day 74’ notice for Epioxa NDA to treat keratoconus